Abstract

Polymorphism of the PDCD1 gene for the PD-1 protein (programmed cell death 1, encoded by PDCD1) is significantly associated with higher incidence of autoimmune diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), which may suggest the participation of PD-1 in the pathogenesis of these diseases. Over 30 single nucleotide polymorphisms (SNPs) have been identified in the human PDCD1 gene. SNPs in the PDCD1 gene in humans have demonstrated relevant associations with a higher risk of developing autoimmune diseases in certain ethnic groups. RA and SLE are chronic connective tissue diseases with autoimmune background. RA is a common form of chronic, progressive arthritis in adults. SLE is characterized by chronic inflammation in most of the body’s tissues and organs, leading to a complex clinical syndrome. The pathogenesis of the autoimmune diseases is not well examined. However, genetic factors, immunological disorders and environmental factors are believed to play a decisive role in the occurrence of the illnesses. Complex immune system disorders are responsible for the development of SLE. In RA activated T cells produce cytokines such as interleukin 2 (IL-2) and interferon γ (IFN-γ) that stimulate macrophages and monocytes. The main role of PD-1 is inhibition of T-cell proliferation, inhibition of production of IL-2, interleukin 10 (IL-10) and IFN-γ, and inhibition of activation of autoreactive lymphocytes. Because of the wide range of ligand distribution in the body, the biological significance of protein refers to almost all aspects of the immune response, including autoimmunology, tumour immunology, inflammation, transplantation, and allergy. Currently, there is increasing interest in the importance of PD-1 in the maintenance of immunological balance and its role in the development of autoimmune diseases. We summarize the PD-1 research in patients with RA and SLE in recent years.

References

• 1. Adhami E.: Calculating the etiology of systemic lupus erythematosus.Med. Hypotheses, 2004; 62: 237-246
  Google Scholar
• 2. Agata Y., Kawasaki A., Nishimura H., Ishida Y., Tsubata T., YagitaH., Honjo T.: Expression of the PD-1 antigen on the surface of stimulatedmouse T and B lymphocytes. Int. Immunol., 1996; 8: 765-772
  Google Scholar
• 3. Bennett F., Luxenberg D., Ling V., Wang I.M., Marquette K., LoweD., Khan N., Veldman G., Jacobs K.A., Valge-Archer V.E., Collins M.,Carreno B.M.: Program death-1 engagement upon TCR activationhas distinct effects on costimulation and cytokine-driven proliferation:attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, andIL-15 responses. J. Immunol., 2003; 170: 711-718
  Google Scholar
• 4. Bertsias G.K., Nakou M., Choulaki C., Raptopoulou A., PapadimitrakiE., Goulielmos G., Kritikos H., Sidiropoulos P., Tzardi M., KardassisD., Mamalaki C., Boumpas D.T.: Genetic, immunologic, and immunohistochemicalanalysis of the programmed death 1/programmeddeath ligand 1 pathway in human systemic lupus erythematosus.Arthritis Rheum., 2009; 60: 207-218
  Google Scholar
• 5. Bijl M., Horst G., Limburg P.C., Kallenberg C.G.: Expression ofcostimulatory molecules on peripheral blood lymphocytes of patientswith systemic lupus erythematosus. Ann. Rheum. Dis., 2001;60: 523-526
  Google Scholar
• 6. Bolstad A.I., Eiken H.G., Rosenlund B., Alarcón-Riquelme M.E.,Jonsson R.: Increased salivary gland tissue expression of Fas, Fasligand, cytotoxic T lymphocyte-associated antigen 4, and programmedcell death 1 in primary Sjögren’s syndrome. Arthritis Rheum.,2003; 48: 174-185
  Google Scholar
• 7. Ding H., Wu X., Wu J., Yagita H., He Y., Zhang J., Ren J., Gao W.:Delivering PD-1 inhibitory signal concomitant with blocking ICOSco-stimulation suppresses lupus-like syndrome in autoimmune BXSBmice. Clin. Immunol., 2006; 118: 258-267
  Google Scholar
• 8. Ferreiros-Vidal I., Gomez-Reino J.J., Barros F., Carracedo A., CarreiraP., Gonzalez-Escribano F., Liz M., Martin J., Ordi J., Vicario J.L.,Gonzalez A.: Association of PDCD1 with susceptibility to systemiclupus erythematosus: evidence of population-specific effects. ArthritisRheum., 2004; 50: 2590-2597
  Google Scholar
• 9. Fife B.T., Pauken K.E.: The role of the PD-1 pathway in autoimmunityand peripheral tolerance. Ann. NY Acad. Sci., 2011; 1217: 45-59
  Google Scholar
• 10. Finger L.R., Pu J., Wasserman R., Vibhakar R., Louie E., HardyR.R., Burrows P.D., Billips L.G.: The human PD-1 gene: complete cDNA,genomic organization, and developmentally regulated expressionin B cell progenitors. Gene, 1997; 197: 177-187
  Google Scholar
• 11. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., NishimuraH., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., HortonH.F., Fouser L., Carter L., Ling V., Bowman M.R., Carreno B.M., CollinsM., Wood C.R., Honjo T.: Engagement of the PD-1 immunoinhibitoryreceptor by a novel B7 family member leads to negative regulationof lymphocyte activation. J. Exp. Med., 2000; 192: 1027-1034
  Google Scholar
• 12. Gianchecchi E., Delfino D.V., Fierabracci A.: Recent insights intothe role of the PD-1/PD-L1 pathway in immunological tolerance andautoimmunity. Autoimmun. Rev., 2013; 12: 1091-1100
  Google Scholar
• 13. Grakoui A., Bromley S.K., Sumen C., Davis M.M., Shaw A.S., AllenP.M., Dustin M.L.: The immunological synapse: a molecular machinecontroling T cel activation. Science, 1999; 285: 221-227
  Google Scholar
• 14. Hatachi S., Iwai Y., Kawano S., Morinobu S., Kobayashi M., KoshibaM., Saura R., Kurosaka M., Honjo T., Kumagai S.: CD4+PD-1+T cellsaccumulate as unique anergic cells in rheumatoid arthritis synovialfluid. J. Rheumatol., 2003; 30: 1410-1419
  Google Scholar
• 15. Ishida M., Iwai Y., Tanaka Y., Okazaki T., Freeman G.J., MinatoN., Honjo T.: Differential expression of PD-L1 and PD-L2, ligands foran inhibitory receptor PD-1, in the cells of lymphohematopoietictissues. Immunol. Lett., 2002; 84: 57-62
  Google Scholar
• 16. Ishida Y., Agata Y., Shibahara K., Honjo T.,: Induced expressionof PD-1, a novel member of the immunoglobulin gene superfamily,upon programmed cell death. EMBO J., 1992; 11: 3887-3895
  Google Scholar
• 17. Iwamoto T., Ikari K., Inoue E., Toyama Y., Hara M., YamanakaH., Tomatsu T., Momohara S., Kamatani N.: Failure to confirm associationbetween PDCD1 polymorphisms and rheumatoid arthritis ina Japanese population. J. Hum. Genet., 2007; 52: 557-560
  Google Scholar
• 18. Jacobson D.L., Gange S.J., Rose N.R., Graham N.M.: Epidemiologyand estimated population burden of selected autoimmune diseases inthe United States. Clin. Immunol. Immunopathol., 1997; 84: 223-243
  Google Scholar
• 19. Kasagi S., Kawano S., Kumagai S.: PD-1 and autoimmunity. Crit.Rev. Immunol., 2011; 31: 265-295
  Google Scholar
• 20. Kasagi S., Kawano S., Okazaki T., Honjo T., Morinobu A., HatachiS., Shimatani K., Tanaka Y., Minato N., Kumagai S.: Anti-programmedcell death 1 antibody reduces CD4+PD-1+ T cells and relievesthe lupus-like nephritis of NZB/W F1 mice. J. Immunol., 2010; 184:2337-2347
  Google Scholar
• 21. Kobayashi M., Kawano S., Hatachi S., Kurimoto C., Okazaki T.,Iwai Y., Honjo T., Tanaka Y., Minato N., Komori T., Maeda S., KumagaiS.: Enhanced expression of programmed death-1 (PD-1)/PD-L1in salivary glands of patients with Sjögren’s syndrome. J. Rheumatol.,2005; 32: 2156-2163
  Google Scholar
• 22. Kong E.K., Prokunina-Olsson L., Wong W.H., Lau C.S., Chan T.M.,Alarcón-Riquelme M., Lau Y.L.: A new haplotype of PDCD1 is associatedwith rheumatoid arthritis in Hong Kong Chinese. ArthritisRheum., 2005; 52: 1058-1062
  Google Scholar
• 23. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S.,Sobel R.A., Weiner H.L., Nabavi N., Glimcher L.H.: B7-1 and B7-2costimulatory molecules activate differentially the Th1/Th2 developmentalpathways: application to autoimmune disease therapy.Cell, 1995; 80: 707-718
  Google Scholar
• 24. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M.,Chernova I., Iwai Y., Long A.J., Brown J.A., Nunes R., Greenfield E.A.,Bourque K., Boussiotis V.A., Carter L.L., Carreno B.M. i wsp.: PD-L2is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol.,2001; 2: 261-268
  Google Scholar
• 25. Lee S.H., Lee Y.A., Woo D.H., Song R., Park E.K., Ryu M.H., KimY.H., Kim K.S., Hong S.J., Yoo M.C., Yang H.I.: Association of the programmedcell death 1 (PDCD1) gene polymorphism with ankylosingspondylitis in the Korean population. Arthritis Res. Ther., 2006; 8:R163
  Google Scholar
• 26. Lin S.C., Yen J.H., Tsai J.J., Tsai W.C., Ou T.T., Liu H.W., Chen C.J.:Association of a programmed death 1 gene polymorphism with thedevelopment of rheumatoid arthritis, but not systemic lupus erythematosus.Arthritis Rheum., 2004; 50: 770-775
  Google Scholar
• 27. Long E.O.: Regulation of immune responses through inhibitoryreceptors. Annu. Rev. Immunol., 1999; 17: 875-904
  Google Scholar
• 28. Miyazaki Y., Tsumiyama K., Yamane T., Ito M., Shiozawa S.:Expansion of PD-1-positive effector CD4 T cells in an experimentalmodel of SLE: contribution to the self-organized criticality theory.Kobe J. Med. Sci., 2013; 59: E64-E71
  Google Scholar
• 29. Mostowska M., Wudarski M., Chwalińska-Sadowska H., Jagodziń-ski P.P.: The programmed cell death 1 gene 7209 C>T polymorphismis associated with the risk of systemic lupus erythematosus in thePolish population. Clin. Exp. Rheumatol., 2008; 26: 457-460
  Google Scholar
• 30. Nielsen C., Hansen D., Husby S., Jacobsen B.B., Lillevang S.T.: Associationof a putative regulatory polymorphism in the PD-1 genewith susceptibility to type 1 diabetes. Tissue Antigens, 2003; 62:492-497
  Google Scholar
• 31. Nishimura H., Nose M., Hiai H., Minato N., Honjo T.: Developmentof lupus-like autoimmune diseases by disruption of the PD-1gene encoding an ITIM motif-carrying immunoreceptor. Immunity,1999; 11: 141-151
  Google Scholar
• 32. Okazaki T., Honjo T.: PD-1 and PD-1 ligands: from discovery toclinical application. Int. Immunol., 2007; 19: 813-824
  Google Scholar
• 33. Okazaki T., Honjo T.: The PD-1 – PD-L pathway in immunologicaltolerance. Trends Immunol., 2006; 27: 195-201
  Google Scholar
• 34. Park Y.B., Lee S.K., Kim D.S., Lee J., Lee C.H., Song C.H.: Elevatedinterleukin-10 levels correlated with disease activity in systemiclupus erythematosus. Clin. Exp. Rheumatol., 1998; 16: 283-288
  Google Scholar
• 35. Paterson D.J., Jefferies W.A., Green J.R., Brandon M.R., CorthesyP., Puklavec M., Williams A.F.: Antigens of activated rat T lymphocytesincluding a molecule of 50,000 Mr detected only on CD positiveT blasts. Mol. Immunol., 1987; 24: 1281-1290
  Google Scholar
• 36. Prokunina L., Castillejo-López C., Oberg F., Gunnarsson I., BergL., Magnusson V., Brookes A.J., Tentler D., Kristjansdóttir H., GröndalG., Bolstad A.I., Svenungsson E., Lundberg I., Sturfelt G., JönssenA. i wsp.: A regulatory polymorphism in PDCD1 is associated withsusceptibility to systemic lupus erythematosus in humans. Nat.Genet., 2002; 32: 666-669
  Google Scholar
• 37. Prokunina L., Padyukov L., Bennet A., de Faire U., Wiman B., PrinceJ., Alfredsson L., Klareskog L., Alarcón-Riquelme M.: Associationof the PD-1.3A allele of the PDCD1 gene in patients with rheumatoidarthritis negative for rheumatoid factor and the shared epitope.Arthritis Rheum., 2004; 50: 1770-1773
  Google Scholar
• 38. Raptopoulou A.P., Bertsias G., Makrygiannakis D., Verginis P.,Kritikos I.,Tzardi M., Klareskog L., Catrina A.I., Sidiropoulos P., BoumpasD.T.: The programmed death 1/programmed death ligand 1inhibitory pathway is up-regulated in rheumatoid synovium andregulates peripheral T cell responses in human and murine arthritis.Arthritis Rheum., 2010; 62: 1870-1880
  Google Scholar
• 39. Shinohara T., Taniwaki M., Ishida Y., Kawaichi M., Honjo T.:Structure and chromosomal localization of the human PD-1 gene(PDCD1). Genomics, 1994; 23: 704-706
  Google Scholar
• 40. Sidorenko S.P., Clark E.A.: The dual-function CD150 receptorsubfamily: the viral attraction. Nat. Immunol., 2003; 4: 19-24
  Google Scholar
• 41. Sinha A.A. Lopez M.T., McDevitt H.O.: Autoimmune diseases: thefailure of self tolerance. Science, 1990; 248: 1380-1388
  Google Scholar
• 42. Tahoori M.T., Pourfathollah A.A., Akhlaghi M., DaneshmandiS., Nicknam M.H., Soleimanifar N.: Association of programmed celldeath-1 (PDCD-1) gene polymorphisms with rheumatoid arthritis inIranian patients. Clin. Exp. Rheumatol., 2011; 29: 763-767
  Google Scholar
• 43. Tokuhiro S., Yamada R., Chang X., Suzuki A., Kochi Y., SawadaT., Suzuki M., Nagasaki M., Ohtsuki M., Ono M., Furukawa H., NagashimaM., Yoshino S., Mabuchi A., Sekine A. i wsp.: An intronic SNPin a RUNX1 binding site of SLC22A4, encoding an organic cationtransporter, is associated with rheumatoid arthritis. Nat. Genet.,2003; 35: 341-348
  Google Scholar
• 44. Vibhakar R., Juan G., Traganos F., Darzynkiewicz Z., Finger L.R.:Activation-induced expression of human programmed death-1 genein T-lymphocytes. Exp. Cell Res., 1997; 232: 25-28
  Google Scholar
• 45. Wan B., Nie H., Liu A., Feng G., He D., Xu R., Zhang Q., Dong C.,Zhang J.Z.: Aberrant regulation of synovial T cell activation by solublecostimulatory molecules in rheumatoid arthritis. J. Immunol.,2006; 177: 8844-8850
  Google Scholar
• 46. Wang G., Hu P., Yang J., Shen G., Wu X.: The effects of PDL-Igon collagen-induced arthritis. Rheumatol. Int., 2011; 31: 513-519
  Google Scholar
• 47. Wang J., Shan Y., Jiang Z., Feng J., Li C., Ma L., Jiang Y.: High frequenciesof activated B cells and T follicular helper cells are correlatedwith disease activity in patients with new-onset rheumatoidarthritis. Clin. Exp. Immunol., 2013; 174: 212-220
  Google Scholar
• 48. Wang S.C., Chen Y.J., Ou T.T., Wu C.C., Tsai W.C., Liu H.W., Yen J.H.:Programmed death-1 gene polymorphisms in patients with systemiclupus erythematosus in Taiwan. J. Clin. Immunol., 2006; 26: 506-511
  Google Scholar

Full text